Indications
Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).
Composition
- Active substance
- difelikefalin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kapruvia
- Active substance
- difelikefalin
- ATC code
- V03AX
- Group
- Various
- Therapeutic area
- Pruritus
- Marketing authorisation holder
- Vifor Fresenius Medical Care Renal Pharma France
- Status
- Authorised
- EU authorisation
- 25 Apr 2022